Aviptadil

• Description:

  Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al[1][2][3][4][5].

• Product Name Alternative:

  Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)

• UNSPSC:

  12352209

• Target:

  SARS-CoV

• Type:

  Peptides

• Related Pathways:

  Anti-infection

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Aviptadil.html

• Purity:

  99.95

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC4=CNC=N4)N

• Molecular Formula:

  C147H238N44O42S

• Molecular Weight:

  3325.80

• References & Citations:

  [1]Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (COVID-AIV) |[2]Jian Hu, et al. Novel Targets of Drug Treatment for Pulmonary Hypertension. Am J Cardiovasc Drugs|[3]Hamidi SA, et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. Respir Res. 2011;12 (1) :141. Published 2011 Oct 26. |[4]Hamidi SA, et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. Respir Res. 2011;12 (1) :141. Published 2011 Oct 26.|[5]Nagahiro I, et al. Vasoactive intestinal peptide ameliorates reperfusion injury in rat lung transplantation. J Heart Lung Transplant. 1998;17 (6) :617-621.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  Launched

• Citation 01:

  Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Res Sq. 2025 Apr 07.

• CAS Number:

  [40077-57-4]